- Pfizer sues to protect Viagra from generic competition
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Axe aims for world peace with Axe Peace, campaign
- FDA approves liquid form of Merck HIV drug Isentress for infants, small children
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has introduced five new generic drugs, the company said.
The drugs launched are:
Potassium chloride extended-release capsules in the 750-mg strength and in bottle count sizes of 100, 500 and 1,000. The drug is a generic version of Nesher Pharmaceuticals' Micro-K10 ExtenCaps and used to treat potassium deficiency.
Sildenafil tablets in the 20-mg strength and in 90-count bottles. The drug is a generic version of Pfizer's Revatio, used to treat pulmonary arterial hypertension.
Nevirapine tablets in the 200-mg strength and 60-count bottles. The drug is a generic version of Boehringer Ingelheim's Viramune, used to treat HIV.
Metaxalone tablets in the 800-mg strength and 100-count bottles. The drug is a generic version of King Pharmaceuticals' Skelaxin, a muscle relaxant.
Warfarin sodium tablets in the 1-mg, 2-mg, 2.5-mg, 3-mg, 4-mg, 5-mg, 6-mg, 7.5-mg and 10-mg strengths and 100-count bottles. The drug is a generic version of Bristol-Myers Squibb's Coumadin, used to prevent blood clots.
The drugs have a total market value of $550 million, Amneal said.
Correction: An earlier version of this story stated that Amneal had introduced sildenafil citrate tablets, based on a statement by the company. According to an updated news release by Amneal, the drug introduced is sildenafil, not sildenafil citrate.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.